JP2008501320A - 細胞保存方法 - Google Patents
細胞保存方法 Download PDFInfo
- Publication number
- JP2008501320A JP2008501320A JP2007513616A JP2007513616A JP2008501320A JP 2008501320 A JP2008501320 A JP 2008501320A JP 2007513616 A JP2007513616 A JP 2007513616A JP 2007513616 A JP2007513616 A JP 2007513616A JP 2008501320 A JP2008501320 A JP 2008501320A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- temperature
- cell suspension
- thawed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 238000004321 preservation Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 263
- 230000008014 freezing Effects 0.000 claims abstract description 57
- 238000007710 freezing Methods 0.000 claims abstract description 55
- 210000000130 stem cell Anatomy 0.000 claims abstract description 53
- 239000006285 cell suspension Substances 0.000 claims abstract description 50
- 238000003860 storage Methods 0.000 claims abstract description 27
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 14
- 230000007774 longterm Effects 0.000 claims abstract description 10
- 238000010257 thawing Methods 0.000 claims description 38
- 230000006910 ice nucleation Effects 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 18
- 238000001816 cooling Methods 0.000 claims description 16
- 230000004913 activation Effects 0.000 claims description 12
- 230000035899 viability Effects 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 8
- 239000002577 cryoprotective agent Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 210000002449 bone cell Anatomy 0.000 claims description 6
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims description 5
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 210000003292 kidney cell Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 210000004927 skin cell Anatomy 0.000 claims description 4
- 238000011476 stem cell transplantation Methods 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 230000006911 nucleation Effects 0.000 claims description 3
- 238000010899 nucleation Methods 0.000 claims description 3
- 210000001612 chondrocyte Anatomy 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000001705 ectoderm cell Anatomy 0.000 claims description 2
- 210000004039 endoderm cell Anatomy 0.000 claims description 2
- 210000000442 hair follicle cell Anatomy 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims description 2
- 210000001704 mesoblast Anatomy 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 238000007654 immersion Methods 0.000 claims 1
- 210000003061 neural cell Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002791 soaking Methods 0.000 claims 1
- 238000005138 cryopreservation Methods 0.000 abstract description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 44
- 239000010902 straw Substances 0.000 description 41
- 230000000694 effects Effects 0.000 description 26
- 239000007788 liquid Substances 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 22
- 239000002609 medium Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 230000008929 regeneration Effects 0.000 description 16
- 238000011069 regeneration method Methods 0.000 description 16
- 101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 13
- 102000029816 Collagenase Human genes 0.000 description 11
- 108060005980 Collagenase Proteins 0.000 description 11
- 229960002424 collagenase Drugs 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 9
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 101150094793 Hes3 gene Proteins 0.000 description 7
- 239000012595 freezing medium Substances 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000004017 vitrification Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- -1 equipment Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 241000277331 Salmonidae Species 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000275 quality assurance Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000003211 trypan blue cell staining Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100519293 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pdx-1 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000004670 early embryonic cell Anatomy 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013411 master cell bank Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229940124553 radioprotectant Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004902933A AU2004902933A0 (en) | 2004-06-02 | Cell preservation method | |
| AU2005902548A AU2005902548A0 (en) | 2005-05-18 | Cell preservation method 2 | |
| PCT/AU2005/000783 WO2005118785A1 (en) | 2004-06-02 | 2005-06-02 | Cell preservation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008501320A true JP2008501320A (ja) | 2008-01-24 |
| JP2008501320A5 JP2008501320A5 (enExample) | 2008-03-13 |
Family
ID=35462905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513616A Pending JP2008501320A (ja) | 2004-06-02 | 2005-06-02 | 細胞保存方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9714412B2 (enExample) |
| EP (1) | EP1765986A4 (enExample) |
| JP (1) | JP2008501320A (enExample) |
| CA (1) | CA2569485C (enExample) |
| GB (1) | GB2429717B (enExample) |
| IL (1) | IL179785A (enExample) |
| WO (1) | WO2005118785A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2021100829A1 (enExample) * | 2019-11-20 | 2021-05-27 |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005118785A1 (en) | 2004-06-02 | 2005-12-15 | Es Cell International Pte Ltd | Cell preservation method |
| US8794013B2 (en) * | 2006-02-10 | 2014-08-05 | Praxair Technology, Inc. | Method and system for nucleation control in a controlled rate freezer (CRF) |
| GB0605450D0 (en) * | 2006-03-17 | 2006-04-26 | Intercytex Ltd | Cell co-culture |
| CA2619547C (en) | 2007-02-06 | 2016-05-17 | Smith International, Inc. | Polycrystalline diamond constructions having improved thermal stability |
| US7942219B2 (en) | 2007-03-21 | 2011-05-17 | Smith International, Inc. | Polycrystalline diamond constructions having improved thermal stability |
| GB0719751D0 (en) | 2007-10-10 | 2007-11-21 | Antoxis Ltd | In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells |
| US9297211B2 (en) | 2007-12-17 | 2016-03-29 | Smith International, Inc. | Polycrystalline diamond construction with controlled gradient metal content |
| AU2010242985B2 (en) | 2009-04-29 | 2015-06-18 | Biolife Solutions, Inc. | Apparatuses and compositions for cryopreservation of cellular monolayers |
| ITTO20090797A1 (it) * | 2009-10-21 | 2011-04-22 | Lucia Maria Moriondo | Metodo e soluzione per la crioconservazione di embrioni umani |
| CA2789915C (en) | 2010-02-19 | 2018-05-01 | Cadila Pharmaceuticals Limited | A pharmaceutical composition of killed cells with substantially retained immunogenicity |
| GB201017315D0 (en) | 2010-10-13 | 2010-11-24 | Antoxis Ltd | Compound |
| WO2013096710A1 (en) * | 2011-12-21 | 2013-06-27 | Biocision, Llc | Method and devices for cryopreservation of biomaterials |
| EP2892996B1 (en) * | 2012-09-07 | 2019-08-14 | BioLamina AB | Stem cell bank |
| GB201222241D0 (en) * | 2012-12-11 | 2013-01-23 | Morris George J | Control of ice formation |
| FR3035407B1 (fr) | 2015-04-23 | 2022-06-17 | Francais Du Sang Ets | Procede de conservation de cellules, tissus ou organes en hypothermie |
| EP3359647A1 (en) | 2015-10-08 | 2018-08-15 | Neurona Therapeutics Inc. | Neural precursor cell populations and uses thereof |
| JP6823074B2 (ja) | 2015-12-07 | 2021-01-27 | クーパーサージカル・インコーポレイテッドＣｏｏｐｅｒＳｕｒｇｉｃａｌ， Ｉｎｃ． | 低温検体キャリヤおよび関連する方法 |
| EP3407844A4 (en) * | 2016-01-29 | 2019-10-16 | Qool Therapeutics, Inc. | AEROSOLISATION OF STEM CELLS OR STEM CELL DERIVATIVES FOR PULMONARY ADMINISTRATION |
| US11352605B2 (en) | 2016-05-12 | 2022-06-07 | Erasmus University Medical Center Rotterdam | Method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium |
| NL2019517B1 (en) | 2017-09-08 | 2019-03-19 | Univ Erasmus Med Ct Rotterdam | New therapy for Pompe disease |
| US20240352425A1 (en) * | 2021-01-19 | 2024-10-24 | Gallant Pet. Inc. | Methods for optimizing reproductive tissue derived cell yield and viability for clinical applications |
| US12471592B2 (en) | 2021-08-18 | 2025-11-18 | Reelabs Private Limited | Cytoprotective compositions for short-term cells storage and transportation without cryopreservation and deep freezing |
| CN116602292A (zh) * | 2023-05-29 | 2023-08-18 | 广西壮族自治区水牛研究所 | 一种利用冻精管冻存生物细胞的方法 |
| WO2025160465A1 (en) | 2024-01-26 | 2025-07-31 | Celularity Inc. | A method of treating signs or symptoms of the aging process |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2330516A (en) * | 1997-10-22 | 1999-04-28 | Elizabeth Acton | Cryopreservation of cell suspensions |
| WO2003102151A2 (en) * | 2002-05-30 | 2003-12-11 | Celgene Corporation | Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors |
| WO2004010780A2 (en) * | 2002-07-30 | 2004-02-05 | General Biotechnology, Llc | Innocuous intracellular ice |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8611894D0 (en) * | 1986-05-15 | 1986-06-25 | Cell Systems Ltd | Biological cryo-protection |
| US5891617A (en) | 1993-09-15 | 1999-04-06 | Organogenesis Inc. | Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing |
| US7504257B2 (en) | 2000-03-14 | 2009-03-17 | Es Cell International Pte Ltd. | Embryonic stem cells and neural progenitor cells derived therefrom |
| CA2524929C (en) | 2003-05-08 | 2015-01-13 | Cellartis Ab | Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method |
| WO2005118785A1 (en) | 2004-06-02 | 2005-12-15 | Es Cell International Pte Ltd | Cell preservation method |
| US7811819B2 (en) * | 2005-05-31 | 2010-10-12 | The University Of Washington | Cryopreservation of primate embryonic stem cells |
-
2005
- 2005-06-02 WO PCT/AU2005/000783 patent/WO2005118785A1/en not_active Ceased
- 2005-06-02 GB GB0625461A patent/GB2429717B/en not_active Expired - Fee Related
- 2005-06-02 US US11/628,443 patent/US9714412B2/en not_active Expired - Fee Related
- 2005-06-02 JP JP2007513616A patent/JP2008501320A/ja active Pending
- 2005-06-02 EP EP05744902A patent/EP1765986A4/en not_active Ceased
- 2005-06-02 CA CA2569485A patent/CA2569485C/en not_active Expired - Fee Related
-
2006
- 2006-12-03 IL IL179785A patent/IL179785A/en active IP Right Grant
-
2017
- 2017-06-08 US US15/617,892 patent/US10472606B2/en not_active Expired - Fee Related
-
2019
- 2019-10-03 US US16/591,985 patent/US20200208104A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2330516A (en) * | 1997-10-22 | 1999-04-28 | Elizabeth Acton | Cryopreservation of cell suspensions |
| WO2003102151A2 (en) * | 2002-05-30 | 2003-12-11 | Celgene Corporation | Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors |
| WO2004010780A2 (en) * | 2002-07-30 | 2004-02-05 | General Biotechnology, Llc | Innocuous intracellular ice |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2021100829A1 (enExample) * | 2019-11-20 | 2021-05-27 | ||
| WO2021100829A1 (ja) * | 2019-11-20 | 2021-05-27 | 大日本住友製薬株式会社 | 神経系細胞の凍結方法 |
| KR20220104764A (ko) | 2019-11-20 | 2022-07-26 | 스미토모 파마 가부시키가이샤 | 신경계 세포의 동결 방법 |
| JP7491533B2 (ja) | 2019-11-20 | 2024-05-28 | 住友ファーマ株式会社 | 神経系細胞の凍結方法 |
| JP2024097884A (ja) * | 2019-11-20 | 2024-07-19 | 住友ファーマ株式会社 | 神経系細胞の凍結方法 |
| JP7787527B2 (ja) | 2019-11-20 | 2025-12-17 | 株式会社Racthera | 神経系細胞の凍結方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005118785A1 (en) | 2005-12-15 |
| GB2429717B (en) | 2009-04-08 |
| US10472606B2 (en) | 2019-11-12 |
| CA2569485A1 (en) | 2005-12-15 |
| IL179785A (en) | 2014-09-30 |
| GB2429717A (en) | 2007-03-07 |
| US20080057040A1 (en) | 2008-03-06 |
| US9714412B2 (en) | 2017-07-25 |
| CA2569485C (en) | 2015-08-18 |
| GB0625461D0 (en) | 2007-02-07 |
| IL179785A0 (en) | 2007-05-15 |
| US20170275588A1 (en) | 2017-09-28 |
| EP1765986A4 (en) | 2007-11-07 |
| US20200208104A1 (en) | 2020-07-02 |
| EP1765986A1 (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10472606B2 (en) | Cell preservation method for pluripotent stem cells | |
| Ji et al. | Cryopreservation of adherent human embryonic stem cells | |
| AU2017377309B2 (en) | Mammalian cell cryopreservation liquid | |
| KR102725720B1 (ko) | 망막 색소 상피 세포 조성물 | |
| CN109843052A (zh) | 用于细胞冷冻保存的组合物和方法 | |
| KR20060032953A (ko) | 폐쇄된 스트로 초자화 방법의 사용에 의한 인간 배반포에서유래된 줄기 세포의 동결 보존 | |
| Marquez-Curtis et al. | Expansion and cryopreservation of porcine and human corneal endothelial cells | |
| US7501231B2 (en) | Methods and compositions for cryopreservation of dissociated primary animal cells | |
| US20250122481A1 (en) | Cryopreservation compositions and methods using red blood cells | |
| AU2005250053B2 (en) | Cell preservation method | |
| Magalhaes et al. | The use of vitrification to preserve primary rat hepatocyte monolayer on collagen-coated poly (ethylene-terephthalate) surfaces for a hybrid liver support system | |
| Chowdhury et al. | Cryopreservation of stem cells | |
| Kubis-Kubiak et al. | New Method of Isolation and Deriving Cell Line from Frozen Nervous Tissue | |
| JP6945487B2 (ja) | 細胞又は組織の凍結保存液 | |
| WO2023175930A1 (ja) | 卵子成熟促進剤及びその用途 | |
| Ferreira | Cryopreservation and Thawing Protocol of Mesenchymal Stem Cells for use in Veterinary Medicine Cell Therapy | |
| Tripathy et al. | Cryopreservation of ovarian tissues: An innovative approach to restore fertility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080123 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080123 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101008 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110107 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110117 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110902 |